Heart Failure (HF)Archives
Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
Heart Failure (HF) 4 min.
Daunorubicin, the first anthracycline class of compounds, was discovered over 60 years ago [1, 2]. Initial study revealed its efficacy against childhood leukemias; however, a number of recipients developed congestive heart failure [3]. A retrospective analysis of 4018 patients showed that development...
The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction
Heart Failure (HF) 7 min.
Heart failure (HF) with preserved ejection fraction (HFpEF) is an important public health problem with a poor prognosis, as approximately half of the patients die within 5-years from their diagnosis. Its prevalence is largely driven by ageing and comorbidities such as diabetes, obesity and kidney disease....
Cross-sectional evaluation of the metabolic vulnerability index in heart failure populations
Heart Failure (HF) 3 min.
Given the high burden of heart failure (HF) mortality, identifying robust risk stratification tools is crucial [1]. High-throughput molecular assays, including metabolomics, have demonstrated the potential to improve HF risk stratification [2]. Specifically, the Metabolic Vulnerability Index (MVX), a...
The nonlinear correlation of neutrophil-lymphocyte ratio on 1-year mortality risk in patients with severe acute heart failure
Heart Failure (HF) 5 min.
Acute heart failure (AHF) is an urgent and serious complication of cardiovascular diseases, characterized by rapid deterioration of cardiac pumping function, posing a significant threat to the patient’s life and health [1]. Acute heart failure often leads to high mortality rates in the Intensive...
